With support from the government of Ontario, Piramal Pharma is investing $5,314,000 to upgrade site infrastructure at their ...
Japan’s Chugai Pharmaceutical and InxMed (Hong Kong) have entered into a worldwide license agreement regarding SPYK04, a ...
Telix recently completed enrollment in the Phase 3 BiPASS study of its proprietary 68Ga-PSMA-PET agents, Illuccix® and Gozellix® for pre-biopsy prostate cancer diagnosis. The ompany has positively ...
BioSpectrum Asia, October 2026. From symptom control to disease modification: can precision biology, new modalities and blood-brain barrier technologies turn neurology's breakthroughs into a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results